{"id":210847,"name":"IPSEN BIOPHARMACEUTICALS, INC.","slug":"ipsen-biopharmaceuticals-inc","state":"MA","country":"United States of America","description":"Biopharmaceutical company","totalSpending":340000,"filings":18,"yearlySpending":[{"year":2021,"income":70000},{"year":2022,"income":70000},{"year":2023,"income":80000},{"year":2024,"income":80000},{"year":2025,"income":40000}],"issues":[{"code":"PHA","display":"Pharmacy"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["RICCHETTI INCORPORATED"],"lobbyists":["JEFF RICCHETTI"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Issues related to the pharmaceutical industry generally;\nIssues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)","Issues related to pharmaceutical industry, generally\nIssues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)","Issues related to pharmaceutical industry, generally\nIssues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)","Issues related to pharmaceutical industry, generally\nIssues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)","Issues related to pharmaceutical industry, generally Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)"]}